Haynes and Boone’s Pharmaceuticals Industry Group provides experience in pharmaceuticals, biotechnology and biosimilars at the intersection of the pharmaceutical, biotechnology, drug delivery and medical device arts. Our attorneys have vast and varied experience in pharmaceuticals and can meet clients’ intellectual property, regulatory and compliance, and business transaction needs. We represent a wide array of emerging growth, middle stage and Fortune 100 companies in the pharmaceutical industry, and have a knowledge base and skill set that is particularly helpful to our clients in this field. Our practitioners represent clients in technology areas such as:

  • Pharmaceutical compounds, compositions, formulations, and methods for the treatment, diagnosis, screening for, and prevention of various cancers, viral and bacterial infections, dementia, substance dependency, and cardiovascular, ocular, neurological, and dermatological diseases, conditions, and symptoms related thereto, including solid and liquid oral formulations, injectables, intranasal sprays, transdermal substrates, and other routes of administration

Selected Representations

  • Represented a major pharmaceutical company in connection with in-licensing Phase 3 compounds and joint control of testing and approval process.
  • Represented a major pharmaceutical company in connection with a long-range joint development and marketing collaboration.
  • Represented a major pharmaceutical company in connection with multiple copromotion agreements.
Show More
Randy Peak in Wall Street Journal: ‘VC Daily: Digital-Health Startups Face Choices as M&A Deals Heat [...]
February 03, 2022

Acquisitions of digital-health startups jumped in 2021, and some observers forecast another wave of consolidation this year. But startups can still succeed as long-term independent companies, says Steve Kraus, a partner with Bessemer Venture Partners. Globally, mergers and acquisitions of digital-health companies climbed to 574 last year from 398 in 2020, according to market tracker CB Insights. W [...]